Search Results

Xellia Pharmaceuticals, a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, has received approval by the US FDA for the manufacture of its first premix bag products at its facility in Cleveland, Ohio, USA.

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals.

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.

Xellia Pharmaceuticals Expands Approved Doses of VANCO READY TM (Ready-to-Use Premixed Vancomycin Injection Bags) Additional room temperature stable Vancomycin Injection Premix doses now approved in the US, and available in October 2020 Doses of 1.25 g, 1.75 g and 750 mg ready-to-use Vancomycin premixes In total, 7 VANCO READY TM doses now US FDA approved COPENHAGEN, Denmark--( BUSINESS WIRE )-- Xellia Pharmaceuticals (‘X

Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections has entered into an agreement to divest Xellia’s Raleigh, North Carolina manufacturing plant to Sagent Pharmaceuticals Inc., (‘Sagent’), a leader of specialty pharmaceutical products with an emphasis on the injectable market.

Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received approval from the US Food and Drug Administration allowing the Company to commence manufacturing of drug products at its Cleveland, Ohio site.

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen® (phenylephrine HCl), the first and only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.